TrialNature communications2026

Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial.

Lu Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.